Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Efficacy, Team × pembrolizumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 10 Carcinoma, Non-Small-Cell Lung 10 Lung Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Neoplasms 4 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 2 Carcinoma, Hepatocellular 2 Biliary Tract Neoplasms 2 Urinary Bladder Neoplasms 1 Uncommon Pathological Types of Lung Cancer 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Skin Neoplasms 1 Sexual Dysfunction, Physiological 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms, Squamous Cell 1 Neoplasm Metastasis 1 NSCLC 1 Motor Activity 1 Lung Squamous Cell Carcinoma Stage IV 1 Lung Diseases, Interstitial 1 Liver Diseases 1 Kidney Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Eunuchism 1 Erectile Dysfunction 1 Efficacy, Team 1

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡